Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7,
View HTML
Toggle Summary SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
First non-azole, orally and IV bioavailable antifungal agent with orphan drug designation for both invasive Aspergillus infections and invasive Candida infections
View HTML
Toggle Summary SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
  Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078   Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned   JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc .
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET.
View HTML
Toggle Summary SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the results of an
View HTML
Toggle Summary SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald's 2 nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET.
View HTML
Toggle Summary SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public
View HTML
Toggle Summary SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The company expects to grant the underwriter a 30-day option to
View HTML